Literature DB >> 28273636

MiR-30b-5p acts as a tumor suppressor, repressing cell proliferation and cell cycle in human hepatocellular carcinoma.

Xian Qin1, Jing Chen2, Long Wu1, Zhisu Liu3.   

Abstract

MicroRNAs have been verified to participate in various biological behaviors of different tumors, via multiple signaling pathways. Many kinds of microRNAs in hepatocellular carcinoma have been researched. However, miR-30b-5p hasn't been included. Our study aim at the impacts of miR-30b-5p on HCC and the pathway it mediating. The results showed miR-30b-5p was significant downregulated in HCC tissues and cell lines. With clinical data, we've discovered miR-30b-5p was correlated with several clinical pathological characteristics, such as survival time, tumor size, HBV infected, pathological stage, differentiation and intrahepatic metastasis. Also we illustrated miR-30b-5p repressed cell proliferation and cell cycle of HCC cell lines. For a further study, we figured out that miR-30b-5p mediated DNMT3A to repress proliferation, meanwhile it targeted USP37 for decelerating cell cycle. This discovery inferred miR-30b-5p a potential favorable biomarker and therapeutic target for HCC diagnosis and treatment.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cell cycle; DNMT3A; Hepatocellular carcinoma; Proliferation; USP37; miR-30b-5p

Mesh:

Substances:

Year:  2017        PMID: 28273636     DOI: 10.1016/j.biopha.2017.02.062

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  26 in total

1.  Verification of candidate microRNA markers for parathyroid carcinoma.

Authors:  Ya Hu; Xiang Zhang; Ming Cui; Zhe Su; Mengyi Wang; Quan Liao; Yupei Zhao
Journal:  Endocrine       Date:  2018-02-16       Impact factor: 3.633

2.  miR-30b-5p inhibits cancer progression and enhances cisplatin sensitivity in lung cancer through targeting LRP8.

Authors:  Haitao Qiu; Xiaokang Shen; Bing Chen; Tianming Chen; Guodong Feng; Shilin Chen; Dongjie Feng; Qiaoshu Xu
Journal:  Apoptosis       Date:  2021-03-29       Impact factor: 4.677

3.  miR-30b-5p inhibits osteoblast differentiation through targeting BCL6.

Authors:  Yan Luo; Feng Zhou; Xiaochun Wu; Yi Li; Bin Ye
Journal:  Cell Cycle       Date:  2022-01-31       Impact factor: 4.534

4.  Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis.

Authors:  Yue Zhang; Chao Wei; Cong-Cong Guo; Rong-Xiu Bi; Jin Xie; Dong-Hui Guan; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-09-14

5.  miR-371-5p suppresses the proliferative and migratory capacity of human nasopharyngeal carcinoma by targeting BCL2.

Authors:  Bifan Deng; Feiqun Su; Ruibin Xie; Weiguang Tang
Journal:  Oncol Lett       Date:  2018-04-12       Impact factor: 2.967

6.  Chi-miR-30b-5p inhibits dermal papilla cells proliferation by targeting CaMKIIδ gene in cashmere goat.

Authors:  Yuelang Zhang; Sizhe Xia; Tianci Wang; Shanhe Wang; Dan Yuan; Fang Li; Xin Wang
Journal:  BMC Genomics       Date:  2020-06-26       Impact factor: 3.969

7.  Overexpression of miR-450 affects the biological behavior of HepG2 cells by targeting DNMT3a.

Authors:  Yan Wang; Lina Wang; Xue Yu; Jianping Duan
Journal:  Onco Targets Ther       Date:  2019-07-01       Impact factor: 4.147

8.  A novel miR-0308-3p revealed by miRNA-seq of HBV-positive hepatocellular carcinoma suppresses cell proliferation and promotes G1/S arrest by targeting double CDK6/Cyclin D1 genes.

Authors:  Xiaoming Dai; Ruixue Huang; Sai Hu; Yao Zhou; Xiaoya Sun; Pucheng Gui; Zijian Yu; Pingkun Zhou
Journal:  Cell Biosci       Date:  2020-02-27       Impact factor: 7.133

9.  A 3-miRNA signature predicts survival of patients with hypopharyngeal squamous cell carcinoma after post-operative radiotherapy.

Authors:  Xinbo Xu; Zhongming Lu; Neil Gross; Guojun Li; Fenghua Zhang; Dapeng Lei; Xinliang Pan
Journal:  J Cell Mol Med       Date:  2019-10-02       Impact factor: 5.310

10.  MiR-30b-5p modulates glioma cell proliferation by direct targeting MTDH.

Authors:  Daobao Zhang; Zhiyong Liu; Niandong Zheng; Honggang Wu; Zhao Zhang; Jianguo Xu
Journal:  Saudi J Biol Sci       Date:  2018-03-08       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.